Oncolytics Biotech (NASDAQ: ONCY) flagged by Nasdaq over sub-$1.00 share price
Rhea-AI Filing Summary
Oncolytics Biotech Inc. reported receiving a letter from Nasdaq on July 20, 2026 stating that its common stock closed below $1.00 per share for 30 consecutive business days, causing non-compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement for the Nasdaq Capital Market.
The common stock will continue trading on the Nasdaq Capital Market under the symbol ONCY while the company has a 180-calendar day compliance period, until January 19, 2027, to regain compliance. Compliance will be restored if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days, subject to Nasdaq staff discretion. If compliance is not regained, the company may qualify for an additional 180 days if it meets other initial listing standards (except the minimum bid price) and notifies Nasdaq of its intent to cure; otherwise, the stock will be subject to delisting. The company plans to monitor its share price and evaluate options but notes there is no assurance it will regain compliance or satisfy all Nasdaq rules.
Positive
- None.
Negative
- Nasdaq bid-price deficiency: ONCY is out of compliance after trading below $1.00 for 30 consecutive business days and faces potential delisting if it cannot regain compliance within the allowed periods.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Minimum Bid Price Requirement: $1.00 per share
Non-compliance trigger period: 30 consecutive business days
Initial compliance period: 180 calendar days
+3 more
6 metrics
Minimum Bid Price Requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement for continued listing
Non-compliance trigger period
30 consecutive business days
Period during which ONCY’s closing bid was below $1.00
Initial compliance period
180 calendar days
Time from July 20, 2026 letter to January 19, 2027 to regain compliance
Compliance period end date
January 19, 2027
End of initial Nasdaq bid-price compliance period
Price threshold to regain compliance
$1.00 per share for ten days
Closing bid must meet or exceed $1.00 for at least ten consecutive business days
Potential additional compliance period
180 calendar days
Possible second period if other initial listing standards are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, market value of publicly held shares, Nasdaq Listing Rule 5550(a)(2), +1 more
5 terms
Minimum Bid Price Requirement regulatory
"compliance with the $1.00 minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"requirement for continued listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Nasdaq Listing Rule 5550(a)(2) regulatory
"as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq compliance issue did Oncolytics Biotech (ONCY) disclose?
Oncolytics Biotech disclosed that Nasdaq notified it on July 20, 2026 that ONCY is not in compliance with the $1.00 minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days.
How long does Oncolytics Biotech (ONCY) have to regain Nasdaq bid-price compliance?
Oncolytics Biotech has an initial 180-calendar day compliance period, lasting until January 19, 2027, to regain the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.
What must Oncolytics Biotech (ONCY) do to regain Nasdaq minimum bid price compliance?
To regain compliance, the closing bid price of ONCY common stock must be at least $1.00 per share for a minimum of ten consecutive business days, subject to Nasdaq staff’s discretion to extend that period.
Can Oncolytics Biotech (ONCY) receive more time beyond January 19, 2027 to cure the deficiency?
ONCY may receive an additional 180-calendar day period if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except the bid-price rule) and notifies Nasdaq of its intent to cure.
Will Oncolytics Biotech (ONCY) be immediately delisted from Nasdaq due to this notice?
No. ONCY’s common stock will continue to trade on the Nasdaq Capital Market while it attempts to regain compliance. However, if it cannot cure the deficiency within the allowed periods, its stock will be subject to delisting.
What actions does Oncolytics Biotech (ONCY) plan regarding the Nasdaq bid-price issue?
The company states it intends to monitor the closing bid price of its common stock and assess available options to regain compliance, but it cautions there is no assurance it will succeed.